Colon Screening Market Expected to Hit US$24.45 Bn by 2032, Says Persistence Market Research

The global colon screening market is witnessing rapid expansion as colorectal cancer (CRC) continues to rank among the most common and deadly cancers worldwide. Valued at US$ 18.7 billion in 2025, the market is projected to reach US$ 24.45 billion by 2032, expanding at a CAGR of 3.9% during the forecast period. Colon screening encompasses a broad range of diagnostic techniques-including colonoscopy, fecal immunochemical tests (FIT), fecal occult blood tests (FOBT), and stool DNA testing-designed to detect colorectal abnormalities at early and treatable stages. The growing prevalence of colorectal cancer, increasing awareness campaigns, and government-backed preventive health initiatives are driving the market forward. Moreover, technological advancements in artificial intelligence (AI)-powered endoscopy, telemedicine integration, and non-invasive testing methods have revolutionized how CRC is detected and managed.

The key growth drivers of the market include the increasing incidence of colorectal cancer, rising geriatric population, greater patient preference for non-invasive screening, and expanded government screening programs. According to the World Health Organization (WHO), over 1.9 million new cases of colorectal cancer were diagnosed globally in 2020, and this number is expected to reach 3.2 million by 2040. Such alarming statistics have prompted nations like the U.S., Japan, Germany, and the U.K. to expand population-wide screening programs. North America leads the global market with a projected 44% share in 2025, owing to advanced healthcare infrastructure, high public awareness, and supportive reimbursement policies. In contrast, the stool-based test segment dominates globally with a 42% market share, primarily due to its affordability, simplicity, and at-home convenience, making it ideal for large-scale screening initiatives.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35162

Key Highlights from the Report

• Stool-based tests to dominate 42% of the market in 2025 due to their non-invasive and cost-effective nature.
• Endoscopic procedures to capture 38% of market share, attributed to high diagnostic accuracy and growing AI adoption.
• North America to lead the global colon screening market with a 44% share by 2025.
• Hospitals remain the largest end-user segment with 46% of the global market share.
• Rapid technological advancements, including AI-assisted colonoscopy tools, to enhance early cancer detection.
• At-home screening and telemedicine integration to fuel participation and accessibility across global populations.

Market Segmentation Analysis

The colon screening market can be segmented by screening type, product type, and end-user, reflecting the diversity of diagnostic options and clinical applications.

By screening type, the market includes stool-based tests, colonoscopy, flexible sigmoidoscopy, capsule endoscopy, and others. Among these, stool-based tests-comprising FIT and guaiac-based fecal occult blood tests (gFOBT)-account for the largest share of 42% in 2025. These methods are non-invasive, cost-effective, and easy to use, enabling mass participation in national screening programs. Many developed nations have integrated these tests into public health frameworks to increase compliance and reduce mortality. Colonoscopy, the gold standard for colorectal cancer detection, holds around 35% market share and remains indispensable for high-risk individuals. It provides over 95% sensitivity for detecting polyps and early-stage cancer. Despite its invasive nature, colonoscopy's accuracy and capability to remove precancerous polyps during screening ensure its continued relevance.

Capsule endoscopy and flexible sigmoidoscopy represent emerging technologies, especially valuable for patients who prefer minimally invasive methods. Capsule endoscopy, which uses a swallowable device to capture intestinal images, is gaining momentum in technologically advanced regions. The integration of AI into colonoscopic procedures is further enhancing image recognition and improving detection rates, supporting innovation-driven market growth through 2032.

When segmented by product type, the market encompasses endoscopes, capsule endoscopes, CT scanners, and test kits & reagents. Endoscopes dominate with 38% market share due to their unparalleled precision in identifying adenomas and malignancies. Enhanced visualization technologies and AI-enabled systems like Medtronic's GI Genius have increased adenoma detection rates by up to 14%. Test kits and reagents, accounting for about 27% of the market, are gaining traction in home-based testing, supported by public programs offering free FIT or FOBT kits. CT scanners are also witnessing rising demand due to the growing use of virtual colonoscopy (CT colonography), especially in the U.K. and Canada, where these less-invasive modalities are included in national health programs.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/colon-screening-market.asp

Regional Insights

North America

North America leads the global colon screening market, projected to hold 44% market share in 2025, driven by high adoption of advanced diagnostic technologies and strong healthcare infrastructure. The United States remains a frontrunner, with initiatives such as the CDC's Colorectal Cancer Control Program (CRCCP) aiming for an 80% screening rate among eligible adults. The rise in at-home screening tests and telehealth services has expanded access, particularly in rural and underserved areas. AI-enabled colonoscopy systems, like Medtronic's GI Genius, have shown measurable improvements in detection rates, contributing to lower mortality and higher survival outcomes. With a projected CAGR of 3.5% through 2032, the region continues to set benchmarks for innovation and participation in colorectal cancer prevention.

Europe

Europe accounts for approximately 24% of the global colon screening market by 2025, with Germany, France, and the U.K. at the forefront of large-scale screening initiatives. Germany's National Cancer Plan promotes biennial FIT/FOBT testing for individuals aged 50-54, followed by colonoscopy for those 55 and older. Similarly, the U.K.'s Bowel Cancer Screening Programme recently lowered the screening age to 50, driving participation to over 60% of the eligible population. The European Commission's Beating Cancer Plan further aims to screen 90% of eligible EU citizens by 2040. Innovations in non-invasive tests such as FIT-DNA and AI-enhanced endoscopic techniques are expected to bolster early detection rates and reduce cancer mortality across the continent.

Asia Pacific

The Asia Pacific region is projected to be the fastest-growing market during the forecast period, fueled by an aging population, increased disease awareness, and expanding access to affordable screening solutions. With over 555,000 new CRC cases in China and 149,000 in Japan in 2020, the region faces a significant public health challenge. Governments across South Korea, Singapore, and Japan are implementing comprehensive national screening programs, offering biennial FIT testing and subsidized colonoscopies. The rise of precision medicine and genetic testing in the region is improving risk assessment and personalizing screening approaches. As telemedicine and digital diagnostics expand, Asia Pacific is expected to play a crucial role in shaping the global colon screening landscape over the next decade.

Market Drivers

The primary driver of the colon screening market is the escalating prevalence of colorectal cancer globally. With lifestyle-related risk factors such as obesity, sedentary behavior, and dietary changes becoming widespread, CRC incidence continues to rise. Governments and healthcare organizations have responded by expanding preventive screening programs and promoting public awareness. For instance, consistent screening could prevent up to 60% of CRC-related deaths, according to the Centers for Disease Control and Prevention (CDC). National initiatives such as the U.K.'s NHS Bowel Cancer Screening Programme and the U.S. CRCCP have substantially increased participation rates. Moreover, technological advancements-like AI-assisted imaging and liquid biopsy screening-are improving diagnostic accuracy, encouraging earlier and more effective interventions. Together, these factors are creating strong momentum for market expansion through 2032.

Market Restraints

Despite substantial progress, the colon screening market faces several restraints. The primary limitation lies in the sensitivity and specificity gaps of certain non-invasive methods such as FIT and FOBT. While FIT exhibits approximately 79% sensitivity for CRC detection, it drops to 24-50% for advanced adenomas, often resulting in missed early-stage diagnoses. Similarly, false negatives can delay treatment and compromise patient outcomes. Furthermore, high costs of colonoscopy procedures, limited access to trained specialists, and screening reluctance among asymptomatic individuals continue to hinder growth, particularly in low- and middle-income regions. Addressing these challenges requires greater investment in awareness campaigns, insurance coverage, and next-generation diagnostic innovations to ensure equitable access to early detection.

Market Opportunities

Rapid advancements in telemedicine, AI-powered diagnostics, and at-home testing are creating new opportunities in the colon screening landscape. The growing popularity of stool DNA and RNA-based tests-such as Cologuard and Colosense-has made at-home screening convenient and reliable, especially for patients unable to visit clinics. Between 2019 and 2023, the U.S. saw a 10% increase in at-home CRC screening participation. Despite this progress, nearly 40% of eligible adults remain unscreened, signaling a massive untapped market. AI technologies are being integrated into colonoscopy systems to enhance lesion detection accuracy, while telehealth platforms allow remote patient engagement and follow-up. Partnerships between healthcare institutions and tech innovators are expected to drive a new wave of precision diagnostics, bridging gaps in screening accessibility and patient adherence globally.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35162

Company Insights

The global colon screening market features a competitive mix of established medical device manufacturers and emerging biotech innovators. These players are focusing on strategic collaborations, product launches, and R&D investments to expand their portfolios and strengthen market presence.

• Olympus Corporation
• PENTAX Medical (Hoya Corporation)
• FUJIFILM Holdings Corporation
• Medtronic
• Ambu A/S
• Baxter (Hillrom & Welch Allyn)
• EndoFresh
• Bracco
• Varay Laborix
• QuidelOrtho Corporation
• Novigenix SA
• Guardant Health, Inc.
• Mainz Biomed N.V.
• Eiken Chemical Co., Ltd.

Market Segmentation

By Screening Type

Stool-Based Tests
Fecal Immunochemical Test (FIT)
Guaiac-Based Fecal Occult Blood Test (gFOBT)
Colonoscopy
Flexible Sigmoidoscopy
Capsule Endoscopy
Others

By Product Type

Endoscopes
CT Scanners
Capsule Endoscopes
Test Kits & Reagents
Others

By End-user

Hospitals
Diagnostic & Imaging Centers
Research & Academic Institutions

Others
By Region

North America
Europe
East Asia
South Asia and Oceania
Middle East and Africa
Latin America

Recent Developments

February 2025 - Mainz Biomed and GANZIMMUN Diagnostics launched an enhanced ColoAlert colorectal cancer screening test in Germany, improving accessibility and prevention efforts.

January 2025 - Geneoscopy raised US$ 105 million to commercialize Colosense, an FDA-approved RNA-based at-home CRC screening test designed for superior gastrointestinal diagnostics.

These developments demonstrate the industry's strong focus on innovation, accessibility, and precision diagnostics, signaling robust future growth.

Conclusion

The colon screening market is entering a pivotal phase of transformation driven by technological innovation, governmental support, and increased patient awareness. As the global burden of colorectal cancer intensifies, early detection through reliable, affordable, and accessible screening tools remains the most effective strategy to save lives. Non-invasive stool-based tests and AI-assisted colonoscopy systems are redefining clinical standards, while at-home and telemedicine-enabled diagnostics are expanding patient reach across demographics. Although sensitivity limitations and regional disparities pose challenges, ongoing investments in digital health, AI, and biomarker-based tests promise to enhance diagnostic precision and patient compliance. By 2032, the market's projected value of US$ 24.45 billion underscores a future where colon cancer screening becomes not only a preventive measure but an integral component of global healthcare systems.

Read More Related Reports:

Geriatric Care Services Market https://www.persistencemarketresearch.com/market-research/geriatric-care-services-market.asp
Outpatient Clinics Market https://www.persistencemarketresearch.com/market-research/outpatient-clinics-market.asp
Dysmenorrhea Treatment Market https://www.persistencemarketresearch.com/market-research/dysmenorrhea-treatment-market.asp
Europe Cosmetic CDMO Market https://www.persistencemarketresearch.com/market-research/europe-cosmetic-cdmo-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.